

June 30<sup>th</sup>, 2022

**Subject : Notification of internal test results for SARS-CoV-2 variants (Version 7.00)**

Dear valued customers,

We, SD Biosensor, Inc., would like to inform you that STANDARD™ Q products for SARS-CoV-2 diagnostic are not affected by **“Alpha(B.1.1.7), Beta(B.1.351), Gamma(P.1), Delta(B.1.617.2), Kappa(B.1.617.1) , Epsilon(B.1.429), Iota(B.1.526), Lambda(C.37), Zeta(P.2), Mu(B.1.621), Omicron(B.1.1.529, BA.1, BA.2, BA.3, BA.4, BA.5) SARS-CoV-2 variants”**. The list of applicable STANDARD™ Q products is as follows.

| No. | Product Name                        | Reference No. |
|-----|-------------------------------------|---------------|
| 1   | STANDARD™ Q COVID-19 Ag Test        | Q-NCOV-01G    |
| 2   | STANDARD™ Q COVID-19 Ag Home Test   | Q-NCOV-03G    |
| 3   | STANDARD™ Q COVID-19 Ag Nasal Test  | Q-NCOV-04G    |
| 4   | STANDARD™ Q COVID/Flu Ag Combo Test | Q-CVFL-01C    |
| 5   | STANDARD™ Q COVID-19 Ag Saliva Test | Q-NCOV-02G    |
| 6   | STANDARD™ i-Q COVID-19 Ag Test      | EQ-NCOV-01G   |
| 7   | STANDARD™ i-Q COVID-19 Ag Home Test | EQ-NCOV-03G   |
| 8   | STANDARD™ Q COVID-19 Ag Test 2.0    | Q-NCOV-07G    |

We verified this through internal test, and detailed information about it is below.

Mutations commonly found in the Alpha (B.1.1.7), Beta(B.1.351), Gamma(P.1), Delta(B.1.617.2), Kappa(B.1.617.1), Epsilon(B.1.429), Iota(B.1.526), Lambda(C.37), Zeta(P.2), Omicron(BA.1, BA.2, BA.3) variants as well as the variants listed in part 1, analytical sensitivity, have been wet-lab tested using recombinant proteins, in the combinations indicated in the table in part 1 and no impact was observed in test performance. The mutations commonly found in the respective strains and in the Omicron(B.1.1.529, BA.4, BA.5) variant (*see the table in part 2, in-silico analysis*) have been analyzed in-silico, and no impact on performance is expected.

**0. Monitoring information**
**0.1 Circulating mutations in nucleocapsid (N) protein**

On a monthly basis, viral genomic sequences of the circulating strains will be gathered using GISAID. The most recent 2000 complete and high coverage entries will be analyzed at least monthly against the reference sequence (Wuhan-Hu-1/2019), and all non-synonymous mutations in the N protein will be identified. The percentage of single mutations and mutation combinations in the N protein will be analyzed. All mutations present in > 5% of the circulating isolates will be defined as “Relevant Mutations”.

**0.2 Variants of Concern/Interest globally**

Additionally, Variants of Concern (VoCs) and Variants of Interest (Vols) by the WHO and the European Centre for Disease Prevention and Control (ECDC), as well as Variants Being Monitored (VBM), VOIs, VOCs and Variants of High Consequence (VOHCs) by the US CDC will be monitored regularly. Isolates from all variants listed above will be monitored on GISAID. The most recent 2000 complete and high coverage entries per variant will be analyzed against the reference sequence (Wuhan-Hu-1/2019), and all non-synonymous mutations in the N protein will be identified. The percentage of single mutations and mutation combinations in the N protein will be analyzed. All mutations present in > 5% of the variant will be defined as “Relevant Mutations” as well.

**1. Analytical sensitivity**
**1.1 Purpose of test**

The purpose of this test is to verify that the sensitivity of STANDARD™ Q products is not affected by SARS-CoV-2 variants by using synthetic recombinant proteins.

**1.2 Specimen of test**

## 1) Specimen (Positive)

Since STANDARD™ Q products target nucleocapsid protein (hereafter, N protein), recombinant N protein of 29 variants were synthesized and used as positive specimen.

| #   | Pango lineage | GISAID ACCESSION ID. EPI_ISL | WHO label |
|-----|---------------|------------------------------|-----------|
| 1-1 | B             | 402125                       | N/A       |
| 1-2 | B.1.1.7       | 835226                       | *Alpha    |
| 1-3 | B.1.351       | 660190                       | *Beta     |
| 1-4 | P.1           | 792680                       | *Gamma    |

|      |           |         |           |
|------|-----------|---------|-----------|
| 1-5  | B.1.617.1 | 1360306 | **Kappa   |
| 1-6  | B.1.617.1 | 1789542 | **Kappa   |
| 1-7  | B.1.617.1 | 1620161 | **Kappa   |
| 1-8  | B.1.617.1 | 1545312 | **Kappa   |
| 1-9  | B.1.617.1 | 1823120 | **Kappa   |
| 1-10 | B.1.617.1 | 1904467 | **Kappa   |
| 1-11 | B.1.617.1 | 1660436 | **Kappa   |
| 1-12 | B.1.617.1 | 1913208 | **Kappa   |
| 1-13 | B.1.617.1 | 1969991 | **Kappa   |
| 1-14 | B.1.617.2 | 1970310 | *Delta    |
| 1-15 | B.1.617.2 | 1660458 | *Delta    |
| 1-16 | B.1.617.2 | 1807318 | *Delta    |
| 1-17 | B.1.617.2 | 1913205 | *Delta    |
| 1-18 | A.23.1    | 925892  | N/A       |
| 1-19 | B.1.429   | 1771435 | **Epsilon |
| 1-20 | B.1.526.2 | 1080752 | N/A       |
| 1-21 | B.1.526   | 1227165 | **Iota    |
| 1-22 | B.1.617.3 | 1704494 | N/A       |
| 1-23 | C.36      | 1936140 | N/A       |
| 1-24 | C.37      | 1111296 | **Lambda  |
| 1-25 | P.2       | 1182578 | **Zeta    |
| 1-26 | B.1.616   | 1239370 | N/A       |
| 1-27 | C.1.2     | 3164100 | ***N/A    |
| 1-28 | BA.1      | 6640917 | Omicron   |
| 1-29 | BA.2*     | 7190366 | Omicron   |

\* In the case of BA.3 variant, wet-testing is omitted since the mutation sites of N protein are same as BA.2.

\* Previously circulating Variants of Concerns

\*\* Previously circulating Variants of Interest

\*\*\* Formerly Monitored Variants

## 2) Specimen (Negative)

| ID                   | PCR result |
|----------------------|------------|
| *Negative human swab | Negative   |

\* Negative human swabs were collected from healthy donors and were confirmed to be negative by PCR (US FDA EUA approved, STANDARD M nCoV Real-Time Detection kit, CFX96).

## 3) Test strip

3 LOTs of test strips were used for the test.

### 1.3 Method of test

- 1) Each of the recombinant N proteins was diluted in successive concentrations.
- 2) The dilutions were spiked with a swab.
- 3) The spiked swab was tested in the same method as the IFU.
- 4) Dilutions of the recombinant N proteins were tested repeatedly 20 times for each LOT of test strips.

### 1.4 Result of test

The recombinant N protein of 29 variants showed a similar limit of detection to the Wuhan-Hu-1 recombinant N protein (#1-1) used as a positive control. Therefore, it was confirmed that the sensitivity of the STANDARD™ Q product was not affected by the 29 variants.

## 2. In-silico analysis

### 2.1 Purpose of test

The purpose of this test is to theoretically verify that STANDARD™ Q products are not affected by SARS-CoV-2 variants.

### 2.2 Method of test

- 1) Compare the region where the variant was mutated (hereinafter, mutation site) with the region that STANDARD™ Q targets to detect SARS-CoV-2 (hereinafter, epitope region).
- 2) If the mutation site corresponds to the epitope region, it is predicted that there is a possibility of affecting the STANDARD™ Q product, and the evaluation result is marked with 'P'.
- 3) If the mutation site does not correspond to the epitope region, it is predicted that there is no possibility of affecting the STANDARD™ Q product, and the evaluation result is marked with 'N'.

### 2.3 Result of test

As a result of in-silico analysis of 57 variants, the mutation sites of 2 variants (#2-14: 1239370, #2-31: 1969991) corresponded to the epitope region. However, it was confirmed that #2-14 and #2-31 did not affect the

sensitivity of STANDARD™ Q products through the test for analytical sensitivity (#1-26 and #1-13).

| #    | Pango lineage            | GISAID ACCESSION ID. EPI_ISL | Dominant Mutation site (amio acid number)                       | Result (P or N) |
|------|--------------------------|------------------------------|---|-----------------|
| 2-1  | B                        | 402125                       | N/A (as standard)   | N/A             |
| 2-2  | A.23.1                   | 925892                       | 202   | N               |
| 2-3  | AT.1                     | 2385327                      | 67, 203, 204  | N               |
| 2-4  | AT.1                     | 1259283                      | 203, 204  | N               |
| 2-5  | B.1.1.7                  | 835226                       | 3, 203, 204, 235  | N               |
| 2-6* | B.1.351                  | 660190                       | 205   | N               |
| 2-7* | B.1.427                  | 1060793                      | 205   | N               |
| 2-8  | B.1.429                  | 1771435                      | 205, 234  | N               |
| 2-9* | B.1.429                  | 1194304                      | 205   | N               |
| 2-10 | B.1.525                  | 2432518                      | 2, 12, 205  | N               |
| 2-11 | B.1.526.1                | 2204920                      | 205, 234  | N               |
| 2-12 | B.1.526.2                | 1080752                      | 13, 202   | N               |
| 2-13 | B.1.526                  | 1227165                      | 199, 234  | N               |
| 2-14 | B.1.616                  | 1239370                      | 325   | P               |
| 2-15 | B.1.617.1                | 1360306                      | 203, 377  | N               |
| 2-16 | B.1.617.2                | 1508996                      | 63, 203, 215, 377   | N               |
| 2-17 | B.1.617.3                | 1704494                      | 67, 203, 377  | N               |
| 2-18 | B.1.621*                 | 1582980                      | 205   | N               |
| 2-19 | C.36                     | 1936140                      | 203, 204, 212   | N               |
| 2-20 | C.37                     | 1111296                      | 13, 203, 204, 214, 366  | N               |
| 2-21 | P.1                      | 792680                       | 80, 203, 204  | N               |
| 2-22 | P.2                      | 1182578                      | 119, 203, 204, 234  | N               |
| 2-23 | P.3                      | 1213573                      | 203, 204  | N               |
| 2-24 | B.1.617.1                | 1789542                      | 203, 377, 385   | N               |
| 2-25 | B.1.617.1                | 1620161                      | 3, 203, 377   | N               |
| 2-26 | B.1.617.1                | 1545312                      | 203, 204  | N               |
| 2-27 | B.1.617.1                | 1823120                      | 203, 236, 377   | N               |
| 2-28 | B.1.617.1                | 1904467                      | 3, 13, 203, 243, 377  | N               |
| 2-29 | B.1.617.1                | 1660436                      | 3, 63, 203, 377   | N               |
| 2-30 | B.1.617.1                | 1913208                      | 30, 203, 377  | N               |
| 2-31 | B.1.617.1                | 1969991                      | 203, 310, 377   | P               |
| 2-32 | B.1.617.2                | 1970310                      | 63, 203, 377, 385   | N               |
| 2-33 | B.1.617.2                | 1660458                      | 63, 203, 377  | N               |
| 2-34 | B.1.617.2                | 1807318                      | 63, 203, 204, 205, 206, 207, 208, 377, 385                      | N               |
| 2-35 | B.1.617.2                | 1913205                      | 63, 203, 215, 377   | N               |
| 2-36 | AY.1                     | 3244751                      | 63, 203, 215, 377   | N               |
| 2-37 | AY.2                     | 3123565                      | 63,203,377  | N               |
| 2-38 | AY.3                     | 3352221                      | 63, 203, 215, 377   | N               |
| 2-39 | AY.3.1                   | 2920875                      | 63, 203, 215, 377   | N               |
| 2-40 | B.1.621*                 | 3477571                      | 205   | N               |
| 2-41 | C.1.2                    | 2695610                      | 13, 204, 384, 203   | N               |
| 2-42 | B.1.1.529                | 6647959                      | 13, 31(deletion), 32(deletion), 33(deletion), 203, 204          | N               |
| 2-43 | BA.1<br>(B.1.1.529.1)    | 6640917                      | 13, 31(deletion), 32(deletion), 33(deletion), 203, 204          | N               |
| 2-44 | BA.2<br>(B.1.1.529.2)    | 7190366                      | 13, 31(deletion), 32(deletion), 33(deletion), 203, 204, 413     | N               |
| 2-45 | BA.3<br>(B.1.1.529.3)    | 7526186                      | 13, 31(deletion), 32(deletion), 33(deletion), 203, 204, 413     | N               |
| 2-46 | B.1.640.1                | 6700813                      | 63, 205, 378  | N               |
| 2-47 | B.1.640.2                | 7181977                      | 22, 205   | N               |
| 2-48 | XD**<br>(Delta and BA.1) | 9879437                      | 63, 203, 215, 377   | N               |
| 2-49 | XE**<br>(BA.1 and BA.2)  | 9177743                      | 13, 31(deletion), 32(deletion), 33(deletion), 203, 204 204, 413 | N               |
| 2-50 | XF**<br>(Delta and BA.1) | 8894978                      | 13, 31(deletion), 32(deletion), 33(deletion), 203, 204          | N               |
| 2-51 | BA.1.1                   | 9754508                      | P13L, E31(deletion),  | N               |

|      |           |           |   |   |
|------|-----------|-----------|---|---|
|      |           |           | R32(deletion), S33(deletion), R203K, G204R                                    |   |
| 2-52 | BA.2.2    | 12417574  | P13L, E31(deletion), R32(deletion), S33(deletion), R203K, G204R, S413R        | N |
| 2-53 | BA.2.12   | 10842022  | P13L, E31(deletion), R32(deletion), S33(deletion), R203K, G204R, S413R        | N |
| 2-54 | BA.2.12.1 | 11490263  | P13L, E31(deletion), R32(deletion), S33(deletion), R203K, G204R, S413R        | N |
| 2-55 | BA.4      | 12043292  | P13L, E31(deletion), R32(deletion), S33(deletion), P151S, R203K, G204R, S413R | N |
| 2-56 | BA.5      | 11903045  | P13L, E31(deletion), R32(deletion), S33(deletion), R203K, G204R, S413R        | N |
| 2-57 | BA.5      | 12307612* | P13L, E31(deletion), R32(deletion), S33(deletion), E136D, R203K, G204R, S413R | N |

\* The identical mutation as found as the dominant mutation in this variant was already tested for #2-6

\*\* XD, XE, XF are characterized by combining with the other two lineages (Delta + Omicron) by considering all mutation site including both spike protein and nucleocapsid protein. However, if only the sequence of nucleocapsid protein is considered, a single lineage can be characterized.

※ Accession number of 12307612 is BA.5 sub lineage with very small portion (7.86 by GISAID, 2022.06.16.)

**3. Final conclusion of the test**

As a result of analytical sensitivity and In-silico analysis, it is verified that STANDARD™ Q products are not affected by “Alpha(B.1.1.7), Beta(B.1.351), Gamma(P.1), Delta(B.1.617.2), Kappa(B.1.617.1), Epsilon(B.1.429), Iota(B.1.526), Lambda(C.37), Zeta(P.2), Omicron(BA.1, BA.2, BA.3) SARS-CoV-2 variants”. In addition, as a result of In-silico analysis, it is verified that STANDARD™ Q products are not affected by “Mu(B.1.621), Omicron(B.1.1.529, BA.4, BA.5) SARS-CoV-2 variants”.

Additionally, based on the United States Food and Drug Administration (FDA) recommendation, variants BA.2, BA.4 and BA.5 will be wet tested for potential changes in assay performance.

**4. Interpretation of test result**

The result of this test should not be the sole basis for the diagnosis; confirmatory testing is required.

**4.1 Negative test result**

A negative test result means that it is unlikely that you have COVID-19. However, even if your test is negative, continue to observe all hygiene and safety measures. If you suspect that you have an infection, contact your doctor/primary care physician.

**4.2 Positive test result**

A positive test result means that it is very likely that you have COVID-19. Please contact your doctor/primary care physician or your local health authority immediately and adhere to the local guidelines regarding self-isolation. Your doctor may require you to undergo a PCR test to confirm the result.

We will continue our efforts to comply with high quality management standards and to maintain a consistent high quality management system to ensure customer's satisfaction and product safety. If you have any questions, please contact our sales representative.

Sincerely,  
Geun-Kuk Song  
QMR  
SD BIOSENSOR, Inc.

